Top Markets
Coin of the day
Bristol-Myers Squibb Company Bristol-Myers Squibb Company

Bristol-Myers Squibb Company

BMY
Pozycja w akcjach #149
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and... Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Cena akcji
$59.43
Kapitalizacja rynkowa
$121.03B
Zmiana (1 dzień)
0.83%
Zmiana (1 rok)
0.90%
Kraj
US
Handel Bristol-Myers Squibb Company (BMY)

Kategoria

Przychody dla Bristol-Myers Squibb Company (BMY)
Przychody w Dec 2025 TTM: $48.19B
Według najnowszych raportów finansowych Bristol-Myers Squibb Company, obecny przychód firmy (TTM) wynosi $48.19B. W roku 2024 firma osiągnęła przychód w wysokości $48.30B wzrost w porównaniu do przychodu z roku 2023, który wynosił $45.01B. Przychód to całkowita kwota dochodu generowana przez firmę ze sprzedaży towarów lub usług. W przeciwieństwie do zysku, nie są odliczane żadne koszty.
Historia przychodów firmy Bristol-Myers Squibb Company od 2000 do 2026
Przychody na koniec każdego roku
Rok Przychody Zmień
2026 (TTM) $48.19B 0.00%
2025 $48.19B -0.22%
2024 $48.30B 7.32%
2023 $45.01B -2.50%
2022 $46.16B -0.49%
2021 $46.39B 9.09%
2020 $42.52B 62.62%
2019 $26.15B 15.89%
2018 $22.56B 8.59%
2017 $20.78B 6.94%
2016 $19.43B 17.31%
2015 $16.56B 4.29%
2014 $15.88B -3.09%
2013 $16.39B -7.01%
2012 $17.62B -17.05%
2011 $21.24B 9.03%
2010 $19.48B 3.59%
2009 $18.81B -8.69%
2008 $20.60B 6.46%
2007 $19.35B 8.00%
2006 $17.91B -6.73%
2005 $19.21B -0.89%
2004 $19.38B -7.25%
2003 $20.89B 15.32%
2002 $18.12B -6.71%
2001 $19.42B 6.63%
2000 $18.22B 0.00%
Przychody podobnych firm lub konkurentów
Firma Przychody Różnica w przychodach Kraj
$65.18B 35.24%
US
$58.74B 21.88%
GB
$94.19B 95.45%
US
$61.16B 26.90%
US
$56.15B 16.51%
CH